Compare OZK & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OZK | GKOS |
|---|---|---|
| Founded | 1903 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.2B | 5.4B |
| IPO Year | 1997 | 2015 |
| Metric | OZK | GKOS |
|---|---|---|
| Price | $48.29 | $111.63 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 13 |
| Target Price | $55.38 | ★ $123.62 |
| AVG Volume (30 Days) | ★ 1.0M | 860.2K |
| Earning Date | 01-15-2026 | 10-29-2025 |
| Dividend Yield | ★ 3.61% | N/A |
| EPS Growth | ★ 1.97 | N/A |
| EPS | ★ 6.20 | N/A |
| Revenue | ★ $1,539,084,000.00 | $469,820,000.00 |
| Revenue This Year | $17.94 | $31.15 |
| Revenue Next Year | $0.86 | $24.15 |
| P/E Ratio | $7.85 | ★ N/A |
| Revenue Growth | 5.38 | ★ 30.38 |
| 52 Week Low | $35.71 | $73.16 |
| 52 Week High | $53.66 | $163.71 |
| Indicator | OZK | GKOS |
|---|---|---|
| Relative Strength Index (RSI) | 61.92 | 75.09 |
| Support Level | $46.47 | $105.88 |
| Resistance Level | $49.28 | $110.87 |
| Average True Range (ATR) | 0.99 | 3.32 |
| MACD | 0.39 | 0.03 |
| Stochastic Oscillator | 74.82 | 100.00 |
Bank OZK is a bank holding company that owns and operates a community bank, Bank of the Ozarks. The bank operates offices in Arkansas, Georgia, Florida, North Carolina, Texas, California, New York and Mississippi. It provides a range of banking services which include deposit services such as checking, savings, money market, time deposit, and individual retirement accounts to loan services like real estate, consumer, commercial, and industrial loans. Apart from providing traditional banking products and services it also provides treasury management, trust and wealth management, financial planning, online banking, and other related services.
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.